Korbiliv 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the treatment of various hepatobiliary disorders. It is indicated for the dissolution of cholesterol gallstones in patients with a functioning gallbladder and radiolucent stones. Additionally, Korbiliv 300 is employed in the management of primary biliary cholangitis (PBC), a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. Ursodeoxycholic Acid acts by reducing cholesterol absorption and secretion, thereby decreasing cholesterol saturation in bile and promoting the gradual dissolution of cholesterol-rich gallstones. Moreover, it exerts cytoprotective effects on hepatocytes by stabilizing cell membranes and improving bile flow, which helps to alleviate cholestasis and reduce liver enzyme levels. The medication is typically administered orally, with dosage tailored according to the patient's condition and response to therapy. Korbiliv 300 is generally well tolerated, though mild gastrointestinal disturbances such as diarrhea or nausea may occur. Contraindications include complete biliary obstruction and hypersensitivity to Ursodeoxycholic Acid. Regular monitoring of liver function tests is recommended during treatment to assess efficacy and detect potential adverse effects. Korbiliv 300 Tablet should be used under medical supervision to ensure optimal therapeutic outcomes.